| Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor–targeted agents: results from a large … DYC Heng, W Xie, MM Regan, MA Warren, AR Golshayan, C Sahi, ... Journal of clinical oncology 27 (34), 5794-5799, 2009 | 2421 | 2009 |
| Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-Specific Antigen Working Group GJ Bubley, M Carducci, W Dahut, N Dawson, D Daliani, M Eisenberger, ... Journal of Clinical Oncology 17 (11), 3461-3467, 1999 | 1141 | 1999 |
| Treatment of muscle‐invasive and advanced bladder cancer in 2020 VG Patel, WK Oh, MD Galsky CA: a cancer journal for clinicians 70 (5), 404-423, 2020 | 823 | 2020 |
| Treatment of patients with metastatic urothelial cancer “unfit” for cisplatin-based chemotherapy MD Galsky, NM Hahn, J Rosenberg, G Sonpavde, T Hutson, WK Oh, ... Journal of Clinical Oncology 29 (17), 2432-2438, 2011 | 688 | 2011 |
| PC3 is a cell line characteristic of prostatic small cell carcinoma S Tai, Y Sun, JM Squires, H Zhang, WK Oh, CZ Liang, J Huang The Prostate 71 (15), 1668-1679, 2011 | 647 | 2011 |
| Effects of ligand activation of peroxisome proliferator-activated receptor γ in human prostate cancer E Mueller, M Smith, P Sarraf, T Kroll, A Aiyer, DS Kaufman, W Oh, ... Proceedings of the National Academy of Sciences 97 (20), 10990-10995, 2000 | 553 | 2000 |
| Management of patients with advanced prostate cancer: the report of the Advanced Prostate Cancer Consensus Conference APCCC 2017 S Gillessen, G Attard, TM Beer, H Beltran, A Bossi, R Bristow, B Carver, ... European urology 73 (2), 178-211, 2018 | 531 | 2018 |
| Consensus report: definition and interpretation of remission in type 2 diabetes MC Riddle, WT Cefalu, PH Evans, HC Gerstein, MA Nauck, WK Oh, ... The Journal of Clinical Endocrinology & Metabolism 107 (1), 1-9, 2022 | 495 | 2022 |
| Management of patients with advanced prostate cancer: recommendations of the St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) 2015 S Gillessen, A Omlin, G Attard, JS de Bono, E Efstathiou, K Fizazi, ... Annals of Oncology 26 (8), 1589-1604, 2015 | 408 | 2015 |
| Management of patients with advanced prostate cancer: report of the advanced prostate cancer consensus conference 2019 S Gillessen, G Attard, TM Beer, H Beltran, A Bjartell, A Bossi, A Briganti, ... European urology 77 (4), 508-547, 2020 | 393 | 2020 |
| A consensus definition of patients with metastatic urothelial carcinoma who are unfit for cisplatin-based chemotherapy MD Galsky, NM Hahn, J Rosenberg, G Sonpavde, T Hutson, WK Oh, ... The lancet oncology 12 (3), 211-214, 2011 | 378 | 2011 |
| A phase I trial of a recombinant vaccinia virus expressing prostate-specific antigen in advanced prostate cancer JP Eder, PW Kantoff, K Roper, GX Xu, GJ Bubley, J Boyden, L Gritz, ... Clinical Cancer Research 6 (5), 1632-1638, 2000 | 368 | 2000 |
| Management of hormone refractory prostate cancer: current standards and future prospects WK OH, PW KANTOFF The Journal of urology 160 (4), 1220-1229, 1998 | 365 | 1998 |
| Phase II trial of gemcitabine plus cisplatin in patients with metastatic urothelial cancer D Kaufman, D Raghavan, M Carducci, EG Levine, B Murphy, J Aisner, ... Journal of Clinical Oncology 18 (9), 1921-1927, 2000 | 337 | 2000 |
| Castration-resistant prostate cancer: AUA Guideline MS Cookson, BJ Roth, P Dahm, C Engstrom, SJ Freedland, M Hussain, ... The Journal of urology 190 (2), 429-438, 2013 | 330 | 2013 |
| The association between germline BRCA2 variants and sensitivity to platinum‐based chemotherapy among men with metastatic prostate cancer MM Pomerantz, S Spisák, L Jia, AM Cronin, I Csabai, E Ledet, AO Sartor, ... Cancer 123 (18), 3532-3539, 2017 | 306 | 2017 |
| Comparative effectiveness of cisplatin-based and carboplatin-based chemotherapy for treatment of advanced urothelial carcinoma MD Galsky, GJ Chen, WK Oh, J Bellmunt, BJ Roth, R Petrioli, L Dogliotti, ... Annals of oncology 23 (2), 406-410, 2012 | 306 | 2012 |
| Functional enhancers at the gene-poor 8q24 cancer-linked locus L Jia, G Landan, M Pomerantz, R Jaschek, P Herman, D Reich, C Yan, ... PLoS genetics 5 (8), e1000597, 2009 | 292 | 2009 |
| EMT-and stroma-related gene expression and resistance to PD-1 blockade in urothelial cancer L Wang, A Saci, PM Szabo, SD Chasalow, M Castillo-Martin, ... Nature communications 9 (1), 3503, 2018 | 286 | 2018 |
| Risk of venous thromboembolism in patients with cancer treated with Cisplatin: a systematic review and meta-analysis S Seng, Z Liu, SK Chiu, T Proverbs-Singh, G Sonpavde, TK Choueiri, ... Journal of clinical oncology 30 (35), 4416-4426, 2012 | 286 | 2012 |
Meredith M. Regan, ScDDana-Farber Cancer Institute, Harvard Medical Schoolכתובת אימייל מאומתת בדומיין ds.dfci.harvard.edu